Innoforce Market Research Report

Company Overview

• Name: Innoforce

• Mission: Innoforce is a premier Contract Development and Manufacturing Organization (CDMO) focused on Advanced Therapy Medicinal Products (ATMP). The company's mission is to accelerate the development and commercialization of innovative products globally through comprehensive technology platforms for high-quality manufacturing.

• Founded By: No information is available

• Founded On: No information is available

• Key People in the Company:

• Guoliang Yu, Ph.D. - Co-Founder and Chairman

• Dewan Zeng, Ph.D., MBA - Chief Executive Officer

• Yuling Li, Ph.D. - Co-Founder and President

• Kenneth Carter, Ph.D. - Global Head of Corporate Development & President of US Operations

• Min Zhu, Ph.D. - Senior VP, CDMO Operations

• Mingliang Chen, CPA, SA, EMBA - VP, Finance and Human Resources

• Headquarters:

• 1500 Fannie Dorsey Road, Sykesville, MD 21784, USA

• No. 376 Fengtu Street, Xiaoshan District, Hangzhou, China

• Number of Employees: No information is available

• Revenue: No information is available

• Company Known For: Innoforce is known for its expertise in the manufacturing of plasmid DNA, RNA, lipid nanoparticles (LNP), exosomes, viral vectors, and cell therapeutics. The company's facilities meet cGMP standards set by the FDA, EMA, and NMPA, ensuring the safeguarding of clients' intellectual property.

Products

Plasmid DNA

• Description: Plasmid DNA is used as a starting material for ATMP, including RNA therapy, viral vector-based cell therapy, and gene therapy.

• Key Features:

• Proprietary technologies for plasmid DNA development and manufacturing.

• Support from pre-clinical through clinical and commercial phases.

• Multiple grades and services including GLP grade, GMP-readi™, and cGMP.

RNA Drug Substance

• Description: Innoforce excels in mRNA technology, supporting the development of mRNA therapeutics.

• Key Features:

• High capping efficiency over 98%.

• High mRNA purity and integrity across linear, circular, and self-amplifying RNA.

• Robust analytical methods for more than 120 assays.

LNP Drug Product

• Description: LNPs are used as delivery systems for mRNA therapies.

• Key Features:

• Proprietary technologies for high-efficiency encapsulation.

• Robust and stable LNP manufacturing processes.

• High storage stability and encapsulation efficiency over 90% with high mRNA concentrations.

Viral Vectors

• Description: Viral vectors play a crucial role in cell and gene therapy development.

• Key Features:

• Expertise in lentiviral, adeno-associated, and retroviral vectors.

• Process scalability up to 500L.

• Adherence to cGMP guidelines.

Recent Developments

• Recent Partnerships and Clearances:

• Innoforce’s partner RNAimmune was granted Investigational New Drug (IND) clearance from the FDA for an RSV mRNA vaccine on 2023-12-19.

• Upcoming Events:

• 2024 Advanced Therapies Week in Miami on 2024-01-11.

• 2024 JP Morgan Week | The Global CDMO Summit in San Francisco on 2024-01-08.

• Conferences and Participations:

• Participation in BioProcess International Fall Digital Week on 2023-11-14.

• Presentation at the Cell & Gene Therapy Manufacturing & Commercialization US (BioProcess International 2023) on 2023-09-19.

Note: No specific information about new products launched or new features added to existing products can be found in the data provided.